| Literature DB >> 34095181 |
Ming Wu1,2,3, Conglin Wang1,2, Zheying Liu2, Li Zhong4, Baojun Yu5, Biao Cheng1,6, Zhifeng Liu1,2,7.
Abstract
Background: Exertional heat stroke (EHS) is a life-threatening injury that can lead to acute kidney injury (AKI). The clinical characteristics of and risk factors for EHS complicated with AKI have been poorly documented.Entities:
Keywords: SOFA; acute kidney injury; heatstroke; mortality; risk factors
Year: 2021 PMID: 34095181 PMCID: PMC8170299 DOI: 10.3389/fmed.2021.678434
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Flow chart of all excluded and included patients.
Comparisons of clinical characteristics between AKI and non-AKI patients with EHS.
| APACHE II score, median (IQR) | 9.0 (7.0–14.0) | 13.0 (9.0–21.0) | <0.001 |
| SOFA score, median (IQR) | 2.0 (2.0–4.0) | 5.0 (3.0–9.0) | <0.001 |
| GCS score, median (IQR) | 12.0 (9.0–14.0) | 10.0 (6.0–13.2) | 0.008 |
| Age (years), median (IQR) | 20.0 (19.0–26.0) | 23.0 (19.0–28.0) | 0.063 |
| WBC (1 ×109/L), median (IQR) | 10.3 (8.5–13.7) | 11.9 (9.4–15.7) | 0.010 |
| Neutrophil (1 ×109/L), median (IQR) | 8.8 (6.3–11.8) | 9.5 (6.7–13.2) | 0.112 |
| Lymphocyte (1 ×109/L), median (IQR) | 1.2 (0.7–1.8) | 0.9 (0.5–2.4) | 0.071 |
| Monocytes (1 ×109/L), median (IQR) | 0.7 (0.4–0.9) | 0.7 (0.4–1.0) | 0.317 |
| Platelets (1 ×109/L), median (IQR) | 174.0 (113.0–226.0) | 113.0 (64.8–207.2) | 0.001 |
| Mean platelet volume (%), median (IQR) | 10.7 (10.1–11.4) | 10.7 (10.2–11.5) | 0.861 |
| Platelet distribution width (%), median (IQR) | 12.5 (11.1–13.6) | 12.4 (11.6–14.1) | 0.254 |
| TBIL (μmol/L), median (IQR) | 15.4 (9.9–24.8) | 16.5 (10.3–40.3) | 0.238 |
| ALT (U/L), median (IQR) | 31.0 (17.0–97.0) | 60.0 (25.0–847.0) | 0.005 |
| AST (U/L), median (IQR) | 54.0 (29.0–133.0) | 96.0 (44.0–422.5) | 0.025 |
| BUN (mmol/L), median (IQR) | 4.9 (4.0–6.0) | 6.8 (5.8–10.0) | <0.001 |
| CR (μmol/L), median (IQR) | 95.0 (78.0–119.0) | 170.0 (149.0–228.0) | <0.001 |
| Cystatin C(mg/L), median (IQR) | 0.9 (0.8–1.0) | 1.2 (1.0–1.8) | <0.001 |
| CK (U/L), median (IQR) | 793.5 (248.5–2,148.2) | 1,110.0 (482.0–3,675.2) | 0.034 |
| CK-MB (ng/ml), median (IQR) | 32.5 (22.0–59.8) | 46.0 (29.2–101.8) | 0.006 |
| MB (ng/ml), median (IQR) | 193.6 (63.2–583.5) | 1,000.0 (469.9–1,000.0) | <0.001 |
| cTNI (pg/ml), median (IQR) | 55.0 (10.0–158.2) | 300.2 (100.0–1,016.8) | 0.015 |
| PT (s), median (IQR) | 15.4 (14.0–17.4) | 17.7 (14.6–27.2) | <0.001 |
| INR, median (IQR) | 1.2 (1.1–1.4) | 1.5 (1.2–2.5) | <0.001 |
| APTT (s), median (IQR) | 38.4 (34.5–43.6) | 41.1 (32.8–78.6) | 0.175 |
| TT (s), median (IQR) | 17.3 (16.5–18.4) | 18.8 (16.8–29.2) | 0.002 |
| FIB (g/L), median (IQR) | 2.6 (2.2–2.9) | 2.3 (1.8–2.8) | 0.015 |
| D-D (mg/L), median (IQR) | 0.8 (0.4–3.5) | 5.3 (1.4–13.1) | <0.001 |
| CRP (mg/dL), median (IQR) | 3.3 (1.8–5.8) | 3.4 (0.9–8.7) | 0.543 |
| PCT (ng/ml), median (IQR) | 1.4 (0.7–3.6) | 2.7 (1.2–5.3) | 0.007 |
| CK ≥ 1,000 U/L, | 43 /98 (43.9%) | 40/76 (52.6%) | 0.252 |
| MB ≥ 1,000 ng/ml, | 14/90 (15.6%) | 38/69 (55.1%) | <0.001 |
| Transfusion | 16/105 (15.2%) | 35/75 (46.7%) | <0.001 |
| Lymphocytopenia <0.8 ×109/L, | 37/105 (35.2%) | 35/81 (43.2%) | 0.268 |
| DIC, | 17/80 (21.2%) | 33/64 (51.6%) | <0.001 |
| Acute liver injury | 66/99 (66.7%) | 64/81(80.0%) | 0.047 |
| 90-day mortality | 1/105(1.0%) | 22/82(26.8%) | <0.001 |
| ICU time (d), median (IQR) | 4.0 (3.0–7.0) | 7.0 (4.0–14.0) | <0.001 |
| Survival time (d), median (IQR) | 90.0 (90.0–90.0) | 90.0 (34.0–90.0) | <0.001 |
| Hospitalization costs (RMB), median (IQR) | 28,925.8 (18,132.1–49,212.0) | 87,689.1 (40,293.0–188,228.3) | <0.001 |
Risk factors for EHS complicated with AKI.
| Lymphocyte | 1.2 (1.0, 1.6) 0.075 | 2.2 (1.2, 3.4) 0.005 |
| Neutrophil | 1.1 (1.0, 1.1) 0.040 | 1.1 (1.0, 1.3) 0.024 |
| PT | 1.1 (1.0, 1.1) 0.004 | 1.0 (1.0, 1.0) 0.274 |
| FIB | 0.8 (0.6, 1.1) 0.239 | 1.3 (0.9, 1.9) 0.172 |
| D-Dimer | 1.1 (1.1, 1.2) <0.001 | 1.1 (1.0, 1.2) 0.034 |
| No | 1.0 | 1.0 |
| Yes | 1.5 (0.8, 2.7) 0.219 | 0.6 (0.2, 1.9) 0.421 |
| No | 1.0 | 1.0 |
| Yes | 6.8 (3.3, 14.3) <0.001 | 6.5 (2.2, 19.1) <0.001 |
| No | 1.0 | 1.0 |
| Yes | 3.9 (1.9, 8.2) <0.001 | 3.5 (0.9, 14.0) 0.076 |
Risk factors for 90-day mortality in EHS complicated with AKI patients.
| APACHE II score | 1.3 (1.2, 1.4) <0.001 | 1.5 (0.9, 2.5) 0.102 |
| SOFA score | 1.5 (1.3, 1.7) <0.001 | 4.1 (1.6, 10.8) 0.004 |
| GCS score | 0.7 (0.5, 0.8) <0.001 | 3.2 (1.2, 8.4) 0.017 |
| MB ≥ 1,000 ng/ml | 7.7 (3.0, 19.9) <0.001 | 7.5 (0.3, 201.2) 0.230 |
| CK ≥ 1,000 U/L | 2.1 (0.9, 4.9) 0.106 | 0.0 (0.0, 0.4) 0.031 |
| DIC | 21.3 (4.9, 92.0) <0.001 | 83.9 (0.2, 36,555.1) 0.153 |
| Cystatin C | 1.8 (1.4, 2.4) <0.001 | 1.5 (0.6, 3.9) 0.399 |
| INR | 1.3 (1.2, 1.5) <0.001 | 0.3 (0.1, 0.7) 0.007 |
| FIB | 0.3 (0.1, 0.4) <0.001 | 0.0 (0.0, 0.1) 0.003 |
| D-dimer | 1.0 (1.0, 1.1) <0.001 | 1.0 (0.9, 1.0) 0.175 |
| Acute liver injury | 9.6 (1.3, 71.4) 0.027 | inf. (0.0, Inf) 0.998 |
Adjust model adjust for: Age.
Figure 2ROC curves in predicting 90-day mortality with AKI patients induced by EHS. (A) The AUC of SOFA score was 0.920 (95%CI 0.842–0.998, P < 0.001), the optimal cutoff was 7.5 scores, the sensitivity was 91.7%, and the specificity was 80.5%. (B) The AUC of GCS score was 0.851 (95%CI 0.739–0.962, P < 0.001), the optimal cutoff was 8.5 scores, the sensitivity was 91.7%, and the specificity was 68.3%.
Figure 3Survival curves of 90-day mortality rate in AKI group and non-AKI group.
Figure 4Survival curves of 90-day mortality rate in different AKI stages.